Patients' Adherence to Tenofovir for the Treatment of Hepatitis B: The Role of Clinical Pharmacists

Document Type : Research Paper


1 Department of Clinical Pharmacy, Faculty of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

2 Student Research Committee, Faculty of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

3 Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

4 Student Research Committee, Department of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.



Tenofovir is an antiviral agent prescribed for patients suffering from hepatitis B. It is associated with some side effects such as reduction in the level of patients’ adherence. The aim of this study was to evaluate the impact of clinical pharmacist consultation on patients’ adherence to the use of Tenofovir. In this prospective study, a total of 80 patients were enrolled into the study and were divided into two groups. Patients in group one, received their medication in a routine clinic manner, while patients in the second group, by clinical pharmacist intervention, received Tenofovir along with verbal and written tips about the drug dosage, side effects, drug interactions, food-drug interactions and administration. Finally, patients’ adherence to their medication was evaluated using a standard scale. Also, adverse drug reaction (ADR) occurrence and some laboratory parameters were recorded for further analysis. The patients' adherences to their medication was higher in case group than the control group in first three month of follow up. Moreover, lower ADRs were observed in patients who received clinical pharmacist consultation. It can be concluded that consultation provided by clinical pharmacist can lead to better adherence to Tenofovir usage, better therapeutic response and better tolerance of side effects.


[1] Ataei B, Khodadoostan M, Pouria B and Adibi P. Tenofovir in treatment of Iranian patients with chronic hepatitis B virus infection: An open-label case series. J. Res. Pharm. Pract. (2016) 5(3): 166-170.
[2] Lok AS, et al. Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis. Hepatology. (2016) 63(1): 284-306.
[3] Agarwal K, et al. Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection. J. Hepatol. (2015) 62(3): 533-540.
[4] Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM and Murad MH. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. (2016) 63(1): 261-283.
[5] Bhatt PA. Being a clinical pharmacist: Expectations and outcomes. Indian J. Pharmacol. (2014) 46 (1): 1-2.
[6] Steiner JF and Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J. Clin. Epidemiol. (1997) 50 (1): 105-116.
[7] Salehi-Vaziri M, Sadeghi F, Almasi Hashiani A, Gholami Fesharaki M and Alavian SM. Hepatitis B Virus Infection in the General Population of Iran: An Updated Systematic Review and Meta-Analysis. Hepat. Mon. (2016) 16(4): e35577.
[8] Kayaaslan B and Guner R. Adverse effects of oral antiviral therapy in chronic hepatitis B. World. J. Hepatol. (2017) 9 (5): 227-241.
[9] Bedimo R, Maalouf NM, Zhang S, Drechsler H and Tebas P. Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents. Aids. (2012) 26(7): 825-831.
[10] Gill US, et al. Assessment of bone mineral density in tenofovir-treated patients with chronic hepatitis B: can the fracture risk assessment tool identify those at greatest risk? J. Infect. Dis. (2015) 211 (3): 374-382.
[11] Fontana RJ. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology. (2009) 49 (5 Suppl): S185-195.
[12] Langness JA, Nguyen M, Wieland A, Everson GT and Kiser JJ. Optimizing hepatitis C virus treatment through pharmacist interventions: Identification and management of drug-drug interactions. World. J. Gastroenterol. (2017) 23 (9): 1618-1626.
[13] Martin MT and Faber DM. Patient satisfaction with the clinical pharmacist and prescribers during hepatitis C virus management. J. Clin. Pharm. Ther. (2016) 41(6): 645-649.
[14] Rodis JL and Kibbe P. Evaluation of medication adherence and quality of life in patients with hepatitis C virus receiving combination therapy. Gastroenterol. Nurs. (2010) 33(5): 368-373.
[15] Marino EL, Alvarez-Rubio L, Miro S, Modamio P, Banos F, Lastra CF and Alberdi-Leniz A. Pharmacist intervention in treatment of patients with genotype 1 chronic hepatitis C. J. Manag. Care. Pharm. (2009) 15 (2): 147-150.
[16] Leape LL, Cullen DJ, Clapp MD, Burdick E, Demonaco HJ, Erickson JI and Bates DW. Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. Jama. (1999) 282 (3): 267-270.
[17] Jameson JP and VanNoord GR. Pharmacotherapy consultation on polypharmacy patients in ambulatory care. Ann. Pharmacother. (2001) 35 (7-8): 835-840.
[18] Esmaily H and Saffaei A. Vitamin D Usage Among Iranian Population: A Toxicity Crisis is on the Way. Oman Med. J. (2019) 34 (2): 174-175.
[19] Krska J, et al. Pharmacist-led medication review in patients over 65: a randomized, controlled trial in primary care. Age. Ageing. (2001) 30(3): 205-211.
[20] Chumney EC and Robinson LC. The effects of pharmacist interventions on patients with polypharmacy. Pharmacy. practice. (2006) 4(3): 103-109.
[21] Galt KA. Cost avoidance, acceptance, and outcomes associated with a pharmacotherapy consult clinic in a Veterans Affairs Medical Center. Pharmacotherapy. (1998) 18(5): 1103-1111.
[22] Mokhtari F, Nikyar Z, Naeini BA, Esfahani AA and Rahmani S. Adverse cutaneous drug reactions: Eight year assessment in hospitalized patients. J. Res. Med. Sci. (2014) 19 (8): 720-725.